Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INMD
INMD logo

INMD Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
14.655
Open
14.640
VWAP
14.55
Vol
409.94K
Mkt Cap
835.77M
Low
14.460
Amount
5.96M
EV/EBITDA(TTM)
3.75
Total Shares
57.48M
EV
302.06M
EV/OCF(TTM)
3.49
P/S(TTM)
2.49
Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.
Show More

Events Timeline

(ET)
2026-06-26
09:00:00
DOMA Perpetual Capital Management Opposes InMode Acquisition Proposal
select
2026-06-24 (ET)
2026-06-24
09:00:00
InMode Receives Acquisition Proposal from M.N. Business at $16.20 per Share
select
2026-05-20 (ET)
2026-05-20
07:10:00
InMode Appoints Dr. Shlomo Nass as Chairman of the Board
select
2026-05-06 (ET)
2026-05-06
07:10:00
Sees FY26 Revenue of $365M-$375M
select
2026-05-06
07:10:00
Yair Malca Resigns as CFO Effective May 5
select
2026-05-06
07:10:00
InMode Q1 Revenue $82.02M, Exceeds Expectations
select
2026-03-13 (ET)
2026-03-13
07:10:00
InMode Authorizes Share Repurchase of Approximately 10% of Shares
select
2026-02-23 (ET)
2026-02-23
07:20:00
InMode Transaction Committee Discontinues Review of Potential Transaction
select

News

Newsfilter
7.0
07-02Newsfilter
Investigation into InMode Ltd. for Possible Securities Law Violations
  • Governance Failures Exposed: Steel Partners Holdings L.P. publicly criticized InMode for a series of governance failures over the past six months, raising concerns that the CEO could acquire the company at a price lower than previously rejected by the board, which has alarmed investors.
  • Insider Trading Allegations: The letter claims that InMode's CEO accumulated approximately 800,000 shares in open-market purchases between February 24 and March 10, 2026, during a narrow window surrounding significant corporate events, suggesting potential insider trading based on material non-public information.
  • Stock Price Impact: Following the March 13, 2026 buyback announcement, InMode's stock price surged nearly 6%, indicating the market's sensitivity to governance issues and management behavior, which could affect investor confidence and the company's future market performance.
  • Legal Consultation Opportunity: The Law Offices of Howard G. Smith are offering legal consultations for InMode investors, encouraging affected investors to reach out for potential claims to recover losses, highlighting the possible implications for corporate governance and shareholder rights.
seekingalpha
8.5
07-01seekingalpha
Steel Partners Raises Concerns Over InMode CEO-Led Buyout Proposal
  • Acquisition Proposal Opposition: Steel Partners has expressed serious concerns regarding the CEO-led buyout proposal at $16.20 per share, arguing that this price is below the previously rejected $18 offer, which could harm shareholder interests.
  • Governance Failure Allegations: Warren G. Lichtenstein, Executive Chairman of Steel Partners, highlighted in a letter that InMode has faced a series of governance failures over the past six months, allowing the CEO to potentially acquire the company at an unfair price, jeopardizing shareholder value.
  • Independent Committee Demand: Steel Partners is urging InMode's board to retain a “truly independent” investment bank and form a “genuinely independent” special committee to ensure the acquisition process is free from CEO Moshe Mizrahy's interference, thereby protecting shareholder interests.
  • Shareholder Dissent: Following Steel Partners' letter, fellow shareholder DOMA Perpetual Capital Management also announced its opposition to the buyout proposal, indicating widespread dissatisfaction with InMode's governance and acquisition process.
Newsfilter
8.5
06-25Newsfilter
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
  • Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
  • Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
  • Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
  • Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
stocktwits
8.5
06-24stocktwits
InMode Stock Surges Following Acquisition Proposal
  • Acquisition Proposal Surge: InMode disclosed an unsolicited buyout proposal from MN Business Strategy, led by CEO Moshe Mizrahy, offering $16.20 per share, representing a 21% premium over Tuesday's closing price, potentially attracting more investor interest.
  • Stock Price Surge: Following the acquisition news, InMode's shares surged 11% in early Wednesday trading, hitting its 200-day moving average for the first time since May 4, indicating a positive market reaction to the proposal.
  • Transaction Value Analysis: According to Koyfin data, InMode has approximately 63.26 million shares outstanding, implying a total transaction value of about $1.03 billion based on the proposed offer price, highlighting the potential impact of this acquisition proposal.
  • Shift in Retail Sentiment: Retail sentiment on Stocktwits shifted from 'neutral' to 'bullish' a day prior to the acquisition announcement, reflecting investor optimism about the company's future prospects, despite the stock only rising about 9% over the past year.
seekingalpha
8.5
06-24seekingalpha
InMode Confirms Unsolicited Takeover Offer, Shares Rise 11%
  • Takeover Offer Confirmation: InMode, an Israeli MedTech company, confirmed an unsolicited takeover offer from M.N. Business Strategy, a group backed by CEO Moshe Mizrahy, indicating strong interest in the company's future prospects.
  • Offer Price Set: The proposal suggests an acquisition price of $16.20 per share, with InMode's board approving a special committee of independent directors to evaluate the bid, highlighting the company's seriousness regarding the potential transaction.
  • Positive Stock Reaction: Following the announcement, InMode shares rose approximately 11% in premarket trading, reflecting the market's positive sentiment towards the acquisition proposal and potentially boosting investor confidence in the company's future.
  • Transaction Uncertainty: Despite the board's evaluation of the offer, InMode stated that it does not guarantee a final transaction or any other strategic outcome, demonstrating a cautious approach to the acquisition process.
PRnewswire
8.5
06-24PRnewswire
InMode Receives Acquisition Proposal
  • Acquisition Proposal Overview: On June 17, 2026, InMode Ltd. received an acquisition proposal from M.N. Business Strategy, offering $16.20 per share in cash for all outstanding ordinary shares not already owned, indicating strong market recognition of the company's value.
  • Board Response: The company's Board has approved the formation of a special committee comprised solely of independent directors to evaluate the proposal, ensuring that the best interests of the company and all shareholders are maintained, demonstrating the company's seriousness regarding the proposal.
  • Evaluation Process Uncertainty: While the special committee will consult with advisors for the evaluation, there is no assurance that this will lead to a transaction or any other strategic outcome, reflecting the company's cautious approach in the face of potential acquisition.
  • Future Outlook: As a leading global provider of innovative medical technologies, InMode is committed to developing and marketing emerging RF technologies, and a potential acquisition could further enhance its market position and technological capabilities.
Wall Street analysts forecast INMD stock price to rise
5 Analyst Rating
Wall Street analysts forecast INMD stock price to rise
1 Buy
4 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
15.00
Averages
17.33
High
21.00
Current: 0.000
sliders
Low
15.00
Averages
17.33
High
21.00
Baird
Baird
Neutral
downgrade
$17 -> $14
AI Analysis
2026-05-07
Reason
Baird
Baird
Price Target
$17 -> $14
AI Analysis
2026-05-07
downgrade
Neutral
Reason
Baird lowered the firm's price target on InMode to $14 from $17 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and where margin pressures accelrated with a its move to Lasers.
Barclays
NULL -> Overweight
downgrade
$21 -> $19
2026-05-07
Reason
Barclays
Price Target
$21 -> $19
2026-05-07
downgrade
NULL -> Overweight
Reason
Barclays lowered the firm's price target on InMode to $19 from $21 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INMD
Unlock Now

Valuation Metrics

The current forward P/E ratio for Inmode Ltd (INMD.O) is 10.96, compared to its 5-year average forward P/E of 13.63. For a more detailed relative valuation and DCF analysis to assess Inmode Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
13.63
Current PE
10.96
Overvalued PE
21.76
Undervalued PE
5.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.43
Current EV/EBITDA
9.53
Overvalued EV/EBITDA
16.09
Undervalued EV/EBITDA
2.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.07
Current PS
2.21
Overvalued PS
8.33
Undervalued PS
1.82

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what are the best day trades for tommarow
Intellectia · 19 candidates
Region: USPrice: $10.00 - $80.00Beta: HighRiskList Exchange: XNYS, XNAS, XASEOne Day Rise Prob: >= 60One Day Predict Return: 2.0% - 10.0%Monthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
ATKR logo
ATKR
Atkore Inc
2.22B
GGAL logo
GGAL
Grupo Financiero Galicia SA
7.64B
MMYT logo
MMYT
MakeMyTrip Ltd
4.03B
ACMR logo
ACMR
ACM Research Inc
3.03B
AEHR logo
AEHR
Aehr Test Systems
1.96B
GME logo
GME
GameStop Corp
10.27B
what are good day trade buys today
Intellectia · 19 candidates
Region: USPrice: $10.00 - $60.00Rsi Category: moderatePrice Change Pct: $5.00 - $18.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA5Monthly Average Dollar Volume: >= 3,000,000Macd: bullish, positive
Ticker
Name
Market Cap$
top bottom
CCL logo
CCL
Carnival Corp
45.93B
NCLH logo
NCLH
Norwegian Cruise Line Holdings Ltd
10.54B
AMPX logo
AMPX
Amprius Technologies Inc
1.62B
DOCN logo
DOCN
DigitalOcean Holdings Inc
5.39B
CUK logo
CUK
Carnival PLC
45.46B
QURE logo
QURE
Uniqure NV
1.49B
stock to buy for day trade
Intellectia · 39 candidates
Price: $5.00 - $80.00Price Change Pct: >= $3.00Relative Vol: >= -100Support Resistance Relationship: PriceBreakResistanceMin5 Price Change Pct: >= $0.00Monthly Average Dollar Volume: >= -100
Ticker
Name
Market Cap$
top bottom
SILC logo
SILC
Silicom Ltd
99.07M
OPTX logo
OPTX
Syntec Optics Holdings Inc
215.89M
VPG logo
VPG
Vishay Precision Group Inc
667.21M
WATT logo
WATT
Energous Corp
15.65M
SIM logo
SIM
Grupo Simec SAB de CV
4.45B
FCAP logo
FCAP
First Capital Inc
166.28M
stocks that will double in the next year
Intellectia · 6 candidates
Beta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 15Return On Equity: >= 15.0%
Ticker
Name
Market Cap$
top bottom
GCT logo
GCT
GigaCloud Technology Inc
1.47B
DFH logo
DFH
Dream Finders Homes Inc
1.83B
XP logo
XP
XP Inc
9.92B
LULU logo
LULU
Lululemon Athletica Inc
22.27B
FSM logo
FSM
Fortuna Mining Corp
3.30B
INMD logo
INMD
Inmode Ltd
892.51M
list a stock with 10x potential
Intellectia · 10 candidates
Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Weekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
FIGS logo
FIGS
Figs Inc
1.90B
DFH logo
DFH
Dream Finders Homes Inc
1.83B
MBIN logo
MBIN
Merchants Bancorp
1.64B
XPEL logo
XPEL
Xpel Inc
1.52B
ARHS logo
ARHS
Arhaus Inc
1.49B
GCT logo
GCT
GigaCloud Technology Inc
1.47B
low market cap stocks only
Intellectia · 15 candidates
Market Cap: 800.00M - 900.00MBeta: HighRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
LIND logo
LIND
Lindblad Expeditions Holdings Inc
896.38M
DJCO logo
DJCO
Daily Journal Corp
895.46M
AEHR logo
AEHR
Aehr Test Systems
894.32M
LDI logo
LDI
loanDepot Inc
893.07M
INMD logo
INMD
Inmode Ltd
892.51M
KRUS logo
KRUS
Kura Sushi USA Inc
891.16M
Next stock that will 100x
Intellectia · 7 candidates
Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
DFH logo
DFH
Dream Finders Homes Inc
1.83B
MBIN logo
MBIN
Merchants Bancorp
1.64B
GCT logo
GCT
GigaCloud Technology Inc
1.47B
OPRA logo
OPRA
Opera Ltd
1.21B
CSTL logo
CSTL
Castle Biosciences Inc
1.20B
INMD logo
INMD
Inmode Ltd
892.51M
Best stocks to 1000x in future
Intellectia · 21 candidates
Market Cap: <= 5.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20
Ticker
Name
Market Cap$
top bottom
CROX logo
CROX
Crocs Inc
4.43B
JOE logo
JOE
St Joe Co
3.75B
PAY logo
PAY
Paymentus Holdings Inc
3.63B
ACMR logo
ACMR
ACM Research Inc
3.47B
FSM logo
FSM
Fortuna Mining Corp
3.30B
BANC logo
BANC
Banc of California Inc
3.28B
Best stock with future potential 100x
Intellectia · 7 candidates
Market Cap: <= 2.00BBeta: HighRiskRevenue 5yr Cagr: >= 20Eps 5yr Cagr: >= 20Pe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
DFH logo
DFH
Dream Finders Homes Inc
1.83B
MBIN logo
MBIN
Merchants Bancorp
1.64B
GCT logo
GCT
GigaCloud Technology Inc
1.47B
OPRA logo
OPRA
Opera Ltd
1.21B
CSTL logo
CSTL
Castle Biosciences Inc
1.20B
INMD logo
INMD
Inmode Ltd
892.51M

Whales Holding INMD

H
Harel Insurance Investments & Financial Services Ltd
Holding
INMD
+10.55%
3M Return
M
Meitav Investment House Ltd
Holding
INMD
+2.60%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Inmode Ltd (INMD) stock price today?

The current price of INMD is 14.54 USD — it has decreased -0.41

What is Inmode Ltd (INMD)'s business?

Inmode Ltd is an Israel-based global provider of energy-based, minimally-invasive surgical medical treatment solutions. Company's products and solutions are primarily designed to address three energy-based treatment categories comprised of: face and body contouring; medical aesthetics; and women’s health. The Company have developed and commercialized products utilizing medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing adipose tissue remodeling. It's RF energy-based proprietary technologies - Radio Frequency Assisted Lipolysis (RFAL), Deep Subdermal Fractional RF, Simultaneous Fat Destruction and Skin Tightening and Deep Heating Collagen Remodeling for skin and human natural openings- represent a paradigm shift in the minimally-invasive aesthetic solutions market. These technologies are used by physicians to remodel subdermal adipose, or fatty tissue in a variety of procedures.

What is the price predicton of INMD Stock?

Wall Street analysts forecast INMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMD is17.33 USD with a low forecast of 15.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Inmode Ltd (INMD)'s revenue for the last quarter?

Inmode Ltd revenue for the last quarter amounts to 82.02M USD, increased 5.32

What is Inmode Ltd (INMD)'s earnings per share (EPS) for the last quarter?

Inmode Ltd. EPS for the last quarter amounts to 0.18 USD, decreased -30.77

How many employees does Inmode Ltd (INMD). have?

Inmode Ltd (INMD) has 660 emplpoyees as of July 08 2026.

What is Inmode Ltd (INMD) market cap?

Today INMD has the market capitalization of 835.77M USD.